Jaemoon Koh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jaemoon Koh has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Doo Hyun Chung
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
68 shared publications - Yoon Kyung Jeon
Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
63 shared publications - Bhumsuk Keam
Department of Internal Medicine Seoul National University Hospital Seoul Republic of Korea
56 shared publications - Sehui Kim
Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
42 shared publications - Seung Geun Song
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
42 shared publications - Dongjoo Lee
Portrai, Inc
41 shared publications
Latest Publications
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (124) , eadz0989
ILC2-derived IL-9 promotes eosinophil-mediated antitumor activity
Innate lymphoid cells (ILCs) regulate tissue immunity, yet their roles in tumor control remain incompletely understood. Here, we combined analyses of human sequencing datasets with genetic ablation mouse models and adoptive transfer experiments to identify that glucocorticoid-induced tumor necrosis factor receptor (GITR) engagement on tumor-infiltrating group 2 ILCs (ILC2s) induced activating transcription factor 3 (ATF3) and robust interleukin-9 (IL-9) production, exceeding the modest coinduction of IL-5 and IL-13. ILC2-derived IL-9 promoted intratumoral eosinophil accumulation by enhancing survival, tissue retention, and cytotoxicity through tumor-induced IL-9 receptor expression. Eosinophil ablation abolished GITR-mediated tumor control, whereas adoptive eosinophil transfer restored it. This IL-9–eosinophil pathway suppressed tumor growth in the absence of adaptive lymphocytes. In human datasets, IL-9 and eosinophil signatures were associated with favorable prognosis in melanoma and lung adenocarcinoma. These findings define an innate pathway linking ILC2s to eosinophil-mediated tumor immunity and support GITR agonism as a therapeutic strategy.
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (124) , eadz0989
ILC2-derived IL-9 promotes eosinophil-mediated antitumor activity
Innate lymphoid cells (ILCs) regulate tissue immunity, yet their roles in tumor control remain incompletely understood. Here, we combined analyses of human sequencing datasets with genetic ablation mouse models and adoptive transfer experiments to identify that glucocorticoid-induced tumor necrosis factor receptor (GITR) engagement on tumor-infiltrating group 2 ILCs (ILC2s) induced activating transcription factor 3 (ATF3) and robust interleukin-9 (IL-9) production, exceeding the modest coinduction of IL-5 and IL-13. ILC2-derived IL-9 promoted intratumoral eosinophil accumulation by enhancing survival, tissue retention, and cytotoxicity through tumor-induced IL-9 receptor expression. Eosinophil ablation abolished GITR-mediated tumor control, whereas adoptive eosinophil transfer restored it. This IL-9–eosinophil pathway suppressed tumor growth in the absence of adaptive lymphocytes. In human datasets, IL-9 and eosinophil signatures were associated with favorable prognosis in melanoma and lung adenocarcinoma. These findings define an innate pathway linking ILC2s to eosinophil-mediated tumor immunity and support GITR agonism as a therapeutic strategy.
- 24 September 2026
- Published by Wiley in Histopathology
Heterogeneity of breast and nodal response to neoadjuvant pembrolizumab‐based chemoimmunotherapy in early triple‐negative breast cancer and its clinical significance
Aims: To characterize the heterogeneity of pathological responses in the breast and regional lymph nodes after neoadjuvant pembrolizumab‐based chemoimmunotherapy in early‐stage triple‐negative breast cancer (TNBC) and to explore their clinical implications. Methods and results: A total of 203 patients with TNBC treated with neoadjuvant chemotherapy combined with pembrolizumab followed by surgery were included. Histopathological features of baseline biopsy and post‐treatment specimens, including residual carcinoma patterns and tumour‐bed features, were systematically reviewed and correlated with treatment response and clinical outcomes. Pathological complete response (pCR) was achieved in 63.1% of patients. Higher histological grade, increased tumour‐infiltrating lymphocytes (TILs), and higher Ki‐67 labelling index were independently associated with pCR. Residual carcinoma patterns and tumour‐bed changes were heterogeneous, with residual disease most commonly presenting as a solitary, confined focus (51.4%). Fibrotic tumour beds were more frequently observed in non‐pCR cases, whereas stromal elastosis was enriched among pCR cases. Nodal responses were also heterogeneous, including complete nodal response (23.6%), non‐response (8.4%), and mixed nodal response (7.4%). Disease recurrence was more frequent among patients without pCR, and among those with multifocal baseline tumours, higher cT stage, rare histological subtypes, low TILs and residual nodal disease. Conclusions: This real‐world study provides a comprehensive pathological characterization of breast and nodal responses after neoadjuvant chemoimmunotherapy in early TNBC, highlighting heterogeneity beyond pCR and ypN staging and offering a more detailed characterization of treatment‐response patterns.
- 24 September 2026
- Published by Wiley in Histopathology
Heterogeneity of breast and nodal response to neoadjuvant pembrolizumab‐based chemoimmunotherapy in early triple‐negative breast cancer and its clinical significance
Aims: To characterize the heterogeneity of pathological responses in the breast and regional lymph nodes after neoadjuvant pembrolizumab‐based chemoimmunotherapy in early‐stage triple‐negative breast cancer (TNBC) and to explore their clinical implications. Methods and results: A total of 203 patients with TNBC treated with neoadjuvant chemotherapy combined with pembrolizumab followed by surgery were included. Histopathological features of baseline biopsy and post‐treatment specimens, including residual carcinoma patterns and tumour‐bed features, were systematically reviewed and correlated with treatment response and clinical outcomes. Pathological complete response (pCR) was achieved in 63.1% of patients. Higher histological grade, increased tumour‐infiltrating lymphocytes (TILs), and higher Ki‐67 labelling index were independently associated with pCR. Residual carcinoma patterns and tumour‐bed changes were heterogeneous, with residual disease most commonly presenting as a solitary, confined focus (51.4%). Fibrotic tumour beds were more frequently observed in non‐pCR cases, whereas stromal elastosis was enriched among pCR cases. Nodal responses were also heterogeneous, including complete nodal response (23.6%), non‐response (8.4%), and mixed nodal response (7.4%). Disease recurrence was more frequent among patients without pCR, and among those with multifocal baseline tumours, higher cT stage, rare histological subtypes, low TILs and residual nodal disease. Conclusions: This real‐world study provides a comprehensive pathological characterization of breast and nodal responses after neoadjuvant chemoimmunotherapy in early TNBC, highlighting heterogeneity beyond pCR and ypN staging and offering a more detailed characterization of treatment‐response patterns.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Flow chart for patient selection and inclusion and exclusion criteria for DSP analysis of this study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Flow chart for patient selection and inclusion and exclusion criteria for DSP analysis of this study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
The most up- or downregulated gene sets in immune cells between IF_PDL1H and ID_PDL1H
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
The most up- or downregulated gene sets in immune cells between IF_PDL1H and ID_PDL1H
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S13 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
The most up- or downregulated gene sets in tumor cells between IF_PDL1L and ID_PDL1H
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S13 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
The most up- or downregulated gene sets in tumor cells between IF_PDL1L and ID_PDL1H
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Clinical and pathological features of 38 patients with lung adenocarcinoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Clinical and pathological features of 38 patients with lung adenocarcinoma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Survival analysis according to subtype of NSCLC in ICI cohort
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Survival analysis according to subtype of NSCLC in ICI cohort
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
The most up- or downregulated gene sets in immune cells between IF_PDL1H and IF_PDL1L
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
The most up- or downregulated gene sets in immune cells between IF_PDL1H and IF_PDL1L
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Publicly available data source and analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Publicly available data source and analysis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
The most up- or downregulated gene sets in tumor cells between IF_PDL1H and ID_PDL1H
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
The most up- or downregulated gene sets in tumor cells between IF_PDL1H and ID_PDL1H